Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Discover How Success by Sesame’s Affordable, Telehealth-Driven Weight Loss Program Combines Compounded Semaglutide, ...

Yvette C. Terrie, RPh, and Danielle Green, RDN, discuss the obesity epidemic and the many benefits of a holistic approach to ...

With pharmaceutical GLP-1 drugs like semaglutide in high demand, Metamorphx offers a plant-based alternative designed to ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

The Food and Drug Administration (FDA) has accepted for review the New ... of patients who achieved body weight loss of 5% or more. Safety and tolerability of semaglutide 25 mg were consistent ...